NAA50: A Potential Drug Target and Biomarker (G80218)

Target Name: NAA50

NCBI ID: G80218

NAA50

NAA50: A Potential Drug Target and Biomarker

NatE catalytic subunit, or NAA50, is a protein that plays a crucial role in the process of N-alpha-acetyltransferase (NAT), which is a critical enzyme in the production of acetyl-CoA, a crucial intermediate in the citric acid cycle. NAA50 is the catalytic subunit of the NAT enzyme, and its function is to transfer the acetyl group from the substrate amino acid to the carbonyl group of the coenzyme A. This conversion is a key step in the production of ATP from ADP and Pi, and it is also the rate-limiting step in the citric acid cycle.

The discovery of NAA50 as a potential drug target and biomarker has significant implications for the development of new treatments for various diseases. NAA50 is a protein that is expressed in high levels in many different tissues and organs, including the brain, heart, and muscle. It is also expressed in the liver, which is a key organ for the production of ATP, and it is involved in the production of a variety of compounds, including neurotransmitters, such as dopamine and GABA.

The ability of NAA50 to catalyze the N-alpha-acetyltransferase reaction has led to its potential as a drug target. One of the main reasons for its potential as a drug target is its involvement in the production of ATP, which is a crucial energy source for the cell. NAA50 is also involved in the production of other compounds that are important for the functioning of the cell, such as neurotransmitters. This makes it an attractive target for drugs that are designed to modulate the activity of NAA50 and improve the production of ATP and other compounds.

In addition to its potential as a drug target, NAA50 has also been identified as a potential biomarker for a variety of diseases. The production of ATP by NAA50 is affected by a variety of factors, including the levels of certain amino acids, such as lysine and arginine. This makes it an attractive target for drugs that are designed to modulate the levels of these amino acids and improve the production of ATP.

NAA50 is also involved in the production of other compounds that are important for the functioning of the cell. For example, it is involved in the production of neurotransmitters, such as dopamine and GABA, which are important for the proper functioning of the brain and nervous system. The levels of these neurotransmitters are affected by a variety of factors, including the levels of certain amino acids, such as lysine and arginine. This makes NAA50 an attractive target for drugs that are designed to modulate the levels of these amino acids and improve the production of neurotransmitters.

In conclusion, NAA50 is a protein that is involved in the production of ATP and other compounds that are important for the functioning of the cell. Its potential as a drug target and biomarker makes it an attractive target for the development of new treatments for various diseases. Further research is needed to fully understand the role of NAA50 in the production of ATP and other compounds, and to develop effective treatments for diseases that are caused by disruptions in its function.

Protein Name: N-alpha-acetyltransferase 50, NatE Catalytic Subunit

Functions: N-alpha-acetyltransferase that acetylates the N-terminus of proteins that retain their initiating methionine (PubMed:19744929, PubMed:22311970, PubMed:21900231, PubMed:27484799). Has a broad substrate specificity: able to acetylate the initiator methionine of most peptides, except for those with a proline in second position (PubMed:27484799). Also displays N-epsilon-acetyltransferase activity by mediating acetylation of the side chain of specific lysines on proteins (PubMed:19744929). Autoacetylates in vivo (PubMed:19744929). The relevance of N-epsilon-acetyltransferase activity is however unclear: able to acetylate H4 in vitro, but this result has not been confirmed in vivo (PubMed:19744929). Component of N-alpha-acetyltransferase complexes containing NAA10 and NAA15, which has N-alpha-acetyltransferase activity (PubMed:16507339, PubMed:29754825, PubMed:27484799, PubMed:32042062). Does not influence the acetyltransferase activity of NAA10 (PubMed:16507339, PubMed:27484799). However, it negatively regulates the N-alpha-acetyltransferase activity of the N-terminal acetyltransferase A complex (also called the NatA complex) (PubMed:32042062). The multiprotein complexes probably constitute the major contributor for N-terminal acetylation at the ribosome exit tunnel, with NAA10 acetylating all amino termini that are devoid of methionine and NAA50 acetylating other peptides (PubMed:16507339, PubMed:27484799). Required for sister chromatid cohesion during mitosis by promoting binding of CDCA5/sororin to cohesin: may act by counteracting the function of NAA10 (PubMed:17502424, PubMed:27422821)

The "NAA50 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NAA50 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets